ACXP Acurx Pharmaceuticals, Inc.
Healthcare$1.92+0.00%OpenMarket Cap: $3.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.42
P/S
0.00
EV/EBITDA
0.80
DCF Value
$5,040.79
FCF Yield
-196.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-153.9%
ROA
-78.6%
ROIC
-108.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-1.7M | $-1.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-1.6M | $-1.6M | $— | — |
| FY null | $0.00 | NaN% | $-8.1M | $-8.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-2.0M | $-2.0M | $— | — |
| Q2 null | $0.00 | NaN% | $-2.3M | $-2.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.1M | $-2.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-2.8M | $-2.8M | $— | — |
| FY null | $0.00 | NaN% | $-14.1M | $-14.1M | $— | — |
| Q3 null | $0.00 | NaN% | $-2.8M | $-2.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-4.1M | $-4.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-4.4M | $-4.4M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-5.1M | $-5.1M | $-7.60 | — |